文献速递肝胆胰外科围术期管理与 ERAS

减重手术同期肝活检的安全性:MBSAQIP数据库分析

Safety of liver biopsy at the time of bariatric surgery: an analysis of the MBSAQIP database.
PubMed 文献 · Surg Endosc · 2021-01-22

基于MBSAQIP 2015-2018数据库分析546532例减重手术患者,其中3.9%同期行肝活检。倾向匹配分析显示肝活检不增加住院时间、出血或输血率、并发症或死亡风险,但延长手术时间约10.7分钟。

要点

  • 减重手术同期肝活检不增加出血、输血、并发症或死亡风险。
  • 肝活检延长手术时间约10.7分钟,但不延长住院时间。
  • 倾向匹配后肝活检与死亡率无统计学显著差异。

核心结论

  • 减重手术同期肝活检是安全的,不增加住院时间、出血并发症、并发症率或死亡风险。

研究设计与样本

  • 回顾性分析MBSAQIP数据库2015-2018年数据,纳入RYGB(43644)和SG(43775)患者,并识别肝活检编码47000、47001、47379,共546532例符合标准。
  • 采用倾向匹配分析评估调整后关联。

主要发现

  • 共21367例(3.9%)行肝活检,其中RYGB中5.5%(8012例)、SG中3.3%(13355例)行肝活检。
  • 未调整分析中死亡率风险增加(患病率比=1.61,p=0.02),但倾向匹配后无统计学显著差异。
  • 出血或输血率无差异(p=0.22,p=0.21)。

临床怎么用

  • 减重手术中可考虑同期行肝活检以评估肝脏病理,不增加出血或住院时间风险。
  • 需权衡肝活检带来的手术时间延长约10.7分钟。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The majority of patients undergoing bariatric surgery have hepatic steatosis. Liver biopsy is not technically difficult to perform at the time of metabolic and bariatric surgery (MBS), but there may be concerns for bleeding complications. The safety of liver biopsy (LBx) at the time of MBS has been studied in single institutional studies but has not been studied on a national level. METHODS: The MBSAQIP database for 2015-2018 was examined. The codes for Roux-en-Y gastric bypass (RYGB) of 43644 and sleeve gastrectomy (SG) 43775 were used along with 47000 (percutaneous liver biopsy), 47001 (percutaneous liver biopsy at time of other procedure), and 47379 (unlisted laparoscopic procedure, liver). Outcomes such as operative time, complications, and length of stay were examined. Propensity-matched analysis was performed to evaluate for adjusted associations. RESULTS: There were 546,532 patients that met our inclusion criteria. Of those, 21,367 (3.9%) underwent LBx. Only 5.5% (8012) of patients undergoing RYGB had a LBx and 3.3% (13,355) of SG patients. Patients who underwent a LBx had a longer operative time before (103 min vs 84 min, p < 0.001) and after propensity matching [regression coefficient (RC): 10.7 (8.87, 12.5)]. There was no increase in length of stay. There was an increased risk in mortality in the unadjusted analysis (prevalence ratio = 1.61, p = 0.02), but when propensity-matched analysis was done, there was no statistically significant difference between the two groups. Concerning bleeding or transfusion, there was no difference in bleeding or rates of transfusion (p= 0.22, p = 0.21). CONCLUSION: Liver biopsy at the time of MBS is safe. It adds operative time, but there is no increase in length of stay, bleeding complications, morbidity, or death.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Clapp B, Dodoo C, Kim J, et al. Safety of liver biopsy at the time of bariatric surgery: an analysis of the MBSAQIP database. Surg Endosc. 2021. PMID: 33483847. doi:10.1007/s00464-021-08297-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。